MASP-2 Antibody, OMS00620646, OMS620646
( DrugBank: MASP-2 antibody / KEGG DRUG: Narsoplimab )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
66 | IgA腎症 | 6 |
66. IgA腎症
臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
Showing 1 to 6 of 6 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2018-000075-33-DE (EUCTR) | 19/12/201920191219 | 01/07/201920190701 | OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN) | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 i ... | IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: MASP-2 Antibody, OMS00620646, OMS620646 Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: ... | Omeros Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 3 | United States;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;Italy;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Singapore;Australia;Bulgaria;Germany;Korea, Republic of;Sweden United States;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;Italy;United Kingdom;Hungary;Czech Re ... | ||
2 | EUCTR2018-000075-33-BE (EUCTR) | 03/10/201820181003 | 31/05/201820180531 | OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN) | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 i ... | IgA nephropathy (IgAN) MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] IgA nephropathy (IgAN) MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy ... | Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: MASP-2 Antibody, OMS00620646, OMS620646 Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: ... | Omeros Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 3 | United States;Taiwan;Slovakia;Greece;Spain;Thailand;Lithuania;Austria;Italy;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Singapore;Australia;Bulgaria;Germany;Korea, Republic of;Sweden United States;Taiwan;Slovakia;Greece;Spain;Thailand;Lithuania;Austria;Italy;United Kingdom;Hungary;C ... | ||
3 | EUCTR2018-000075-33-BG (EUCTR) | 05/09/201820180905 | 19/07/201820180719 | OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN) | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 i ... | IgA nephropathy (IgAN) MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] IgA nephropathy (IgAN) MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephrop ... | Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: MASP-2 Antibody, OMS00620646, OMS620646 Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: ... | Omeros Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 3 | United States;Taiwan;Slovakia;Greece;Thailand;Spain;Italy;India;Australia;China;Korea, Republic of;Czechia;Lithuania;Turkey;Austria;United Kingdom;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Singapore;Bulgaria;Germany;Sweden United States;Taiwan;Slovakia;Greece;Thailand;Spain;Italy;India;Australia;China;Korea, Republic of;C ... | ||
4 | EUCTR2018-000075-33-SE (EUCTR) | 03/09/201820180903 | 03/05/201820180503 | OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN) | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 i ... | IgA nephropathy (IgAN) MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] IgA nephropathy (IgAN) MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy ... | Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: MASP-2 Antibody, OMS00620646, OMS620646 Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: ... | Omeros Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 3 | United States;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;United Kingdom;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Singapore;Australia;Bulgaria;Germany;China;Sweden;Korea, Republic of United States;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;United Kingdom;Hungary;Czech Republic ... | ||
5 | EUCTR2018-000075-33-SK (EUCTR) | 21/06/201820180621 | 20/04/201820180420 | OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN) | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 i ... | IgA nephropathy (IgAN) MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] IgA nephropathy (IgAN) MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy ... | Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: MASP-2 Antibody, OMS00620646, OMS620646 Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: ... | Omeros Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 3 | United States;Philippines;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Malaysia;Singapore;Australia;Bulgaria;Germany;Sweden;Korea, Republic of United States;Philippines;Taiwan;Slovakia;Spain;Thailand;Lithuania;Austria;United Kingdom;Hungary;Cz ... | ||
6 | EUCTR2018-000075-33-LT (EUCTR) | 15/06/201820180615 | 23/04/201820180423 | OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN) | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) - ARTEMIS-IGAN A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 i ... | IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: MASP-2 Antibody, OMS00620646, OMS620646 Product Name: Narsoplimab Product Code: OMS721 INN or Proposed INN: Narsoplimab Other descriptive name: ... | Omeros Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 3 | United States;Taiwan;Slovakia;Greece;Thailand;Spain;Lithuania;Austria;Italy;United Kingdom;Hungary;Czech Republic;Canada;Poland;Belgium;Singapore;Australia;Bulgaria;Germany;Korea, Republic of;Sweden United States;Taiwan;Slovakia;Greece;Thailand;Spain;Lithuania;Austria;Italy;United Kingdom;Hungary;C ... |